István Májer

867 total citations
52 papers, 561 citations indexed

About

István Májer is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, István Májer has authored 52 papers receiving a total of 561 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 14 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in István Májer's work include Multiple Myeloma Research and Treatments (15 papers), Protein Degradation and Inhibitors (10 papers) and Global Health Care Issues (7 papers). István Májer is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), Protein Degradation and Inhibitors (10 papers) and Global Health Care Issues (7 papers). István Májer collaborates with scholars based in United States, Switzerland and United Kingdom. István Májer's co-authors include Johan P. Mackenbach, Pieter van Baal, Wilma J. Nusselder, Anton E. Kunst, Bart Klijs, Valentin Brodszky, László Gulàcsi, I Boncz, Johan P. Mackenbach and Márta Péntek and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Public Health.

In The Last Decade

István Májer

49 papers receiving 536 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
István Májer United States 14 165 124 100 93 83 52 561
Jay Greenberg United States 18 207 1.3× 56 0.5× 45 0.5× 74 0.8× 36 0.4× 29 1.0k
Christopher S. Parker United States 10 259 1.6× 42 0.3× 25 0.3× 40 0.4× 43 0.5× 14 1.2k
Anna Chodos United States 13 158 1.0× 72 0.6× 53 0.5× 42 0.5× 41 0.5× 28 1.0k
Ventura Sj United States 7 108 0.7× 34 0.3× 68 0.7× 35 0.4× 20 0.2× 8 606
Boxiong Tang United States 16 100 0.6× 23 0.2× 6 0.1× 83 0.9× 57 0.7× 55 671
Beverley Botting United Kingdom 18 168 1.0× 44 0.4× 46 0.5× 314 3.4× 23 0.3× 37 1.3k
Motti Haimi Israel 14 149 0.9× 15 0.1× 34 0.3× 49 0.5× 14 0.2× 44 655
Erika Mosor Austria 11 48 0.3× 61 0.5× 13 0.1× 24 0.3× 24 0.3× 34 342
Mohammad Zakaria Pezeshki Iran 14 75 0.5× 10 0.1× 19 0.2× 145 1.6× 37 0.4× 55 545
Lorena López-González United States 10 72 0.4× 49 0.4× 5 0.1× 51 0.5× 32 0.4× 32 391

Countries citing papers authored by István Májer

Since Specialization
Citations

This map shows the geographic impact of István Májer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by István Májer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites István Májer more than expected).

Fields of papers citing papers by István Májer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by István Májer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by István Májer. The network helps show where István Májer may publish in the future.

Co-authorship network of co-authors of István Májer

This figure shows the co-authorship network connecting the top 25 collaborators of István Májer. A scholar is included among the top collaborators of István Májer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with István Májer. István Májer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Weisel, Katja, Meletios Α. Dimopoulos, Meral Beksaç, et al.. (2024). Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison. Leukemia & lymphoma. 65(4). 481–492. 3 indexed citations
4.
Kastritis, Efstathios, Ioannis Ntanasis‐Stathopoulos, Foteini Theodorakakou, et al.. (2024). Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece. Clinical Lymphoma Myeloma & Leukemia. 24(7). 468–477. 1 indexed citations
5.
Brethon, Benoît, et al.. (2023). Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France. PharmacoEconomics - Open. 7(4). 639–653. 1 indexed citations
6.
Májer, István, et al.. (2021). Estimating and Extrapolating Survival Using a State-Transition Modeling Approach: A Practical Application in Multiple Myeloma. Value in Health. 25(4). 595–604. 5 indexed citations
7.
Nahi, Hareth, Göran Wålinder, Ying Qu, et al.. (2021). Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden. Acta Haematologica. 144(5). 519–527. 2 indexed citations
8.
Májer, István, et al.. (2020). Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States. Expert Review of Hematology. 13(6). 687–696. 3 indexed citations
9.
10.
Májer, István, et al.. (2019). Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology. PharmacoEconomics. 37(5). 727–737. 5 indexed citations
11.
Májer, István, et al.. (2018). PSY63 - COST BY OUTCOMES ANALYSIS OF NOVEL TRIPLE-COMBINATION THERAPIES FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN BRAZIL. Value in Health. 21. S446–S446. 1 indexed citations
12.
Májer, István, et al.. (2015). Cost-Effectiveness of Palivizumab In Children With Congenital Heart Disease In Mexico. Value in Health. 18(7). A830–A830. 2 indexed citations
13.
Emery, Paul, Caitlyn T. Solem, István Májer, Joseph C. Cappelleri, & M. Tarallo. (2015). A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization. Rheumatology International. 35(11). 1837–1849. 18 indexed citations
14.
Heeg, Bart, István Májer, Jennifer Stephens, & M. Tarallo. (2013). A Model to Evaluate the Immunogenicity Costs of Tumour Necrosis Factor-Alpha Inhibitors in Patients with Rheumatoid Arthritis. Value in Health. 16(7). A563–A563. 1 indexed citations
15.
16.
Charokopou, M., Bart Heeg, & István Májer. (2012). RE1 Factors Influencing Drug Reimbursement Decision in Scotland. Value in Health. 15(7). A287–A287. 1 indexed citations
17.
Májer, István, Wilma J. Nusselder, Johan P. Mackenbach, & Anton E. Kunst. (2011). Life Expectancy and Life Expectancy With Disability of Normal Weight, Overweight, and Obese Smokers and Nonsmokers in Europe. Obesity. 19(7). 1451–1459. 28 indexed citations
18.
Májer, István, Wilma J. Nusselder, Johan P. Mackenbach, Bart Klijs, & Pieter van Baal. (2011). Mortality Risk Associated With Disability: A Population-Based Record Linkage Study. American Journal of Public Health. 101(12). e9–e15. 85 indexed citations
19.
Májer, István, et al.. (2010). Socioeconomic inequalities in life and health expectancies around official retirement age in 10 Western-European countries. Journal of Epidemiology & Community Health. 65(11). 972–979. 72 indexed citations
20.
Májer, István, et al.. (2010). Cost-Effectiveness of a Chemoprophylactic Intervention with Single Dose Rifampicin in Contacts of New Leprosy Patients. PLoS neglected tropical diseases. 4(11). e874–e874. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jay Greenberg Breakdown of academic impact, for papers by Christopher S. Parker Breakdown of academic impact, for papers by Anna Chodos Breakdown of academic impact, for papers by Ventura Sj Breakdown of academic impact, for papers by Boxiong Tang Breakdown of academic impact, for papers by Beverley Botting Breakdown of academic impact, for papers by Motti Haimi Breakdown of academic impact, for papers by Erika Mosor Breakdown of academic impact, for papers by Mohammad Zakaria Pezeshki Breakdown of academic impact, for papers by Lorena López-González
Rankless by CCL
2026